Lazard Asset Management
VNDA icon

Lazard Asset Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Lazard Asset Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-35,541
Closed -$163K – 2552
2025
Q1 		$163K Buy
35,541
+11,778
+50% +$54.9K ﹤0.01% 1684
2024
Q4 		$113K Sell
23,763
-79,349
-77% -$381K ﹤0.01% 1766
2024
Q3 		$483K Buy
103,112
+98,516
+2,144% +$528K ﹤0.01% 1365
2024
Q2 		$25K Buy
4,596
+3,266
+246% +$16.9K ﹤0.01% 2007
2024
Q1 		$5K Sell
1,330
-1,307
-50% -$5.23K ﹤0.01% 1902
2023
Q4 		$11K Sell
2,637
-9,047
-77% -$36.5K ﹤0.01% 2094
2023
Q3 		$50K Buy
11,684
+1,966
+20% +$10.9K ﹤0.01% 1859
2023
Q2 		$64K Buy
9,718
+7,041
+263% +$45.1K ﹤0.01% 1747
2023
Q1 		$18K Sell
2,677
-995
-27% -$7K ﹤0.01% 2074
2022
Q4 		$27K Hold
3,672
– – ﹤0.01% 2078
2022
Q3 		$36K Hold
3,672
– – ﹤0.01% 1928
2022
Q2 		$40K Hold
3,672
– – ﹤0.01% 1909
2022
Q1 		$41K Sell
3,672
-28
-0.8% -$368 ﹤0.01% 1836
2021
Q4 		$58K Buy
3,700
+481
+15% +$8.38K ﹤0.01% 1670
2021
Q3 		$55K Sell
3,219
-328
-9% -$5.75K ﹤0.01% 1641
2021
Q2 		$76K Hold
3,547
– – ﹤0.01% 1429
2021
Q1 		$53K Buy
3,547
+963
+37% +$15.6K ﹤0.01% 1412
2020
Q4 		$33K Buy
2,584
+1,805
+232% +$21.7K ﹤0.01% 1539
2020
Q3 		$7K Sell
779
-2,822
-78% -$30.2K ﹤0.01% 1519
2020
Q2 		$41K Sell
3,601
-3,062
-46% -$34.7K ﹤0.01% 1283
2020
Q1 		$69K Buy
6,663
+3,663
+122% +$45.4K ﹤0.01% 1086
2019
Q4 		$49K Buy
3,000
+1,704
+131% +$25.8K ﹤0.01% 1066
2019
Q3 		$17K Buy
+1,296
New +$18.1K ﹤0.01% 1121

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Lazard Asset Management's VNDA Position: Q2 2025 in Review

Lazard Asset Management sold out of Vanda Pharmaceuticals (VNDA) in Q2 2025, closing a stake of 35,541 shares — an estimated $163K sold.

Lazard Asset Management first reported a position in VNDA in Q3 2019 and held it in 23 quarters. The position peaked at $483K in Q3 2024. 139 funds tracked by Wall St. Rank hold VNDA as of Q2 2025.

  • Lazard Asset Management reported no remaining Vanda Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Lazard Asset Management sold 35,541 Vanda Pharmaceuticals shares in Q2 2025, an estimated $163K.
  • Lazard Asset Management first reported a position in Vanda Pharmaceuticals in Q3 2019 and held it in 23 quarters.
  • Lazard Asset Management's Vanda Pharmaceuticals position peaked at $483K in Q3 2024.
  • 139 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2025.

Based on Lazard Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.